Reuters |
EU approves Sanofi and Regeneron's dupilumab in eczema
Reuters Atopic dermatitis is a chronic type of skin inflammation also known as eczema, which in severe cases causes constant, and often unbearable, itching. A human monoclonal antibody, Dupixent is designed to specifically inhibit two key proteins which are … Sanofi's Dupixent gets Europe eczema nod Sanofi, Regeneron claim EU approval for eczema drug Dupixent Regeneron and Sanofi Announce Approval of DUPIXENT® (dupilumab) to Treat Adult Patients with Moderate-to … |